Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 270 entries
Sorted by: Best Match Show Resources per page
Comparing Outcomes of Kinect Videogame-Based Occupational/Physical Therapy Versus Usual Care.

Games for health journal

Dahl-Popolizio S, Loman J, Cordes CC.
PMID: 26196174
Games Health J. 2014 Jun;3(3):157-61. doi: 10.1089/g4h.2014.0002. Epub 2014 Apr 17.

OBJECTIVE: The purpose of this study was to assess the effectiveness of a game-like exercise tool as a component of occupational and physical therapy treatment for patients with shoulder pain and impairment in an outpatient physical therapy clinic.MATERIALS AND...

Cite
Dahl-Popolizio S, Loman J, Cordes CC. Comparing Outcomes of Kinect Videogame-Based Occupational/Physical Therapy Versus Usual Care. Games Health J. 2014;3(3):157-61doi: 10.1089/g4h.2014.0002.
Dahl-Popolizio, S., Loman, J., & Cordes, C. C. (2014). Comparing Outcomes of Kinect Videogame-Based Occupational/Physical Therapy Versus Usual Care. Games for health journal, 3(3), 157-61. https://doi.org/10.1089/g4h.2014.0002
Dahl-Popolizio, Sue, et al. "Comparing Outcomes of Kinect Videogame-Based Occupational/Physical Therapy Versus Usual Care." Games for health journal vol. 3,3 (2014): 157-61. doi: https://doi.org/10.1089/g4h.2014.0002
Dahl-Popolizio S, Loman J, Cordes CC. Comparing Outcomes of Kinect Videogame-Based Occupational/Physical Therapy Versus Usual Care. Games Health J. 2014 Jun;3(3):157-61. doi: 10.1089/g4h.2014.0002. Epub 2014 Apr 17. PMID: 26196174.
Copy Download .nbib Format: NLM
Osteogenic stem cell selection for repair and regeneration.

Bone reports

Tillotson M, Logan N, Brett P.
PMID: 28326344
Bone Rep. 2016 Jan 28;5:22-32. doi: 10.1016/j.bonr.2016.01.003. eCollection 2016 Dec.

The first osteogenic cells to attach to a titanium (Ti) implant after placement are the multipotent stromal cells (MSCs) that circulate in the bloodstream and are recruited to the site of tissue damage. The reservoirs of these cells are...

Cite
Tillotson M, Logan N, Brett P. Osteogenic stem cell selection for repair and regeneration. Bone Rep. 2016;5:22-32doi: 10.1016/j.bonr.2016.01.003.
Tillotson, M., Logan, N., & Brett, P. (2016). Osteogenic stem cell selection for repair and regeneration. Bone reports, 522-32. https://doi.org/10.1016/j.bonr.2016.01.003
Tillotson, Marcus, et al. "Osteogenic stem cell selection for repair and regeneration." Bone reports vol. 5 (2016): 22-32. doi: https://doi.org/10.1016/j.bonr.2016.01.003
Tillotson M, Logan N, Brett P. Osteogenic stem cell selection for repair and regeneration. Bone Rep. 2016 Jan 28;5:22-32. doi: 10.1016/j.bonr.2016.01.003. eCollection 2016 Dec. PMID: 28326344; PMCID: PMC4926815.
Copy Download .nbib Format: NLM
The state of the art in prediction of breast cancer relapse using cell-free circulating tumor DNA liquid biopsies.

Annals of translational medicine

Loman N, Saal LH.
PMID: 27868036
Ann Transl Med. 2016 Oct;4:S68. doi: 10.21037/atm.2016.10.58.

No abstract available.

Cite
Loman N, Saal LH. The state of the art in prediction of breast cancer relapse using cell-free circulating tumor DNA liquid biopsies. Ann Transl Med. 2016;4:S68doi: 10.21037/atm.2016.10.58.
Loman, N., & Saal, L. H. (2016). The state of the art in prediction of breast cancer relapse using cell-free circulating tumor DNA liquid biopsies. Annals of translational medicine, 4S68. https://doi.org/10.21037/atm.2016.10.58
Loman, Niklas, and Saal, Lao H. "The state of the art in prediction of breast cancer relapse using cell-free circulating tumor DNA liquid biopsies." Annals of translational medicine vol. 4 (2016): S68. doi: https://doi.org/10.21037/atm.2016.10.58
Loman N, Saal LH. The state of the art in prediction of breast cancer relapse using cell-free circulating tumor DNA liquid biopsies. Ann Transl Med. 2016 Oct;4:S68. doi: 10.21037/atm.2016.10.58. PMID: 27868036; PMCID: PMC5104597.
Copy Download .nbib Format: NLM
Quality assurance guidelines for superficial hyperthermia clinical trials: I. Clinical requirements.

International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group

Trefná HD, Crezee H, Schmidt M, Marder D, Lamprecht U, Ehmann M, Hartmann J, Nadobny J, Gellermann J, van Holthe N, Ghadjar P, Lomax N, Abdel-Rahman S, Bert C, Bakker A, Hurwitz MD, Diederich CJ, Stauffer PR, van Rhoon GC.
PMID: 28049386
Int J Hyperthermia. 2017 Jun;33(4):471-482. doi: 10.1080/02656736.2016.1277791. Epub 2017 Jan 31.

Quality assurance guidelines are essential to provide uniform execution of clinical trials and treatment in the application of hyperthermia. This document provides definitions for a good hyperthermia treatment and identifies the clinical conditions where a certain hyperthermia system can...

Cite
Trefná HD, Crezee H, Schmidt M, et al. Quality assurance guidelines for superficial hyperthermia clinical trials: I. Clinical requirements. Int J Hyperthermia. 2017;33(4):471-482doi: 10.1080/02656736.2016.1277791.
Trefná, H. D., Crezee, H., Schmidt, M., Marder, D., Lamprecht, U., Ehmann, M., Hartmann, J., Nadobny, J., Gellermann, J., van Holthe, N., Ghadjar, P., Lomax, N., Abdel-Rahman, S., Bert, C., Bakker, A., Hurwitz, M. D., Diederich, C. J., Stauffer, P. R., & van Rhoon, G. C. (2017). Quality assurance guidelines for superficial hyperthermia clinical trials: I. Clinical requirements. International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group, 33(4), 471-482. https://doi.org/10.1080/02656736.2016.1277791
Trefná, Hana Dobšíček, et al. "Quality assurance guidelines for superficial hyperthermia clinical trials: I. Clinical requirements." International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group vol. 33,4 (2017): 471-482. doi: https://doi.org/10.1080/02656736.2016.1277791
Trefná HD, Crezee H, Schmidt M, Marder D, Lamprecht U, Ehmann M, Hartmann J, Nadobny J, Gellermann J, van Holthe N, Ghadjar P, Lomax N, Abdel-Rahman S, Bert C, Bakker A, Hurwitz MD, Diederich CJ, Stauffer PR, van Rhoon GC. Quality assurance guidelines for superficial hyperthermia clinical trials: I. Clinical requirements. Int J Hyperthermia. 2017 Jun;33(4):471-482. doi: 10.1080/02656736.2016.1277791. Epub 2017 Jan 31. PMID: 28049386.
Copy Download .nbib Format: NLM
Increased Nitric Oxide Production Prevents Airway Hyperresponsiveness in Caveolin-1 Deficient Mice Following Endotoxin Exposure.

Journal of allergy & therapy

Hsia BJ, Pastva AM, Giamberardino CD, Potts-Kant EN, Foster WM, Que LG, Abraham SN, Wright JR, Zaas DW.
PMID: 24273688
J Allergy Ther. 2012 Jan 25;(4). doi: 10.4172/2155-6121.S1-004.

BACKGROUND: Caveolin-1, the hallmark protein of caveolae, is highly expressed within the lung in the epithelium, endothelium, and in immune cells. In addition to its classical roles in cholesterol metabolism and endocytosis, caveolin-1 has also been shown to be...

Cite
Hsia BJ, Pastva AM, Giamberardino CD, et al. Increased Nitric Oxide Production Prevents Airway Hyperresponsiveness in Caveolin-1 Deficient Mice Following Endotoxin Exposure. J Allergy Ther. 2012;(4)doi: 10.4172/2155-6121.S1-004.
Hsia, B. J., Pastva, A. M., Giamberardino, C. D., Potts-Kant, E. N., Foster, W. M., Que, L. G., Abraham, S. N., Wright, J. R., & Zaas, D. W. (2012). Increased Nitric Oxide Production Prevents Airway Hyperresponsiveness in Caveolin-1 Deficient Mice Following Endotoxin Exposure. Journal of allergy & therapy, (4), . https://doi.org/10.4172/2155-6121.S1-004
Hsia, Bethany J, et al. "Increased Nitric Oxide Production Prevents Airway Hyperresponsiveness in Caveolin-1 Deficient Mice Following Endotoxin Exposure." Journal of allergy & therapy vol. ,4 (2012). doi: https://doi.org/10.4172/2155-6121.S1-004
Hsia BJ, Pastva AM, Giamberardino CD, Potts-Kant EN, Foster WM, Que LG, Abraham SN, Wright JR, Zaas DW. Increased Nitric Oxide Production Prevents Airway Hyperresponsiveness in Caveolin-1 Deficient Mice Following Endotoxin Exposure. J Allergy Ther. 2012 Jan 25;(4). doi: 10.4172/2155-6121.S1-004. PMID: 24273688; PMCID: PMC3836011.
Copy Download .nbib Format: NLM
Draft Genome Sequence of Elizabethkingia meningoseptica Isolated from a Traumatic Wound.

Genome announcements

Quick J, Constantinidou C, Pallen MJ, Oppenheim B, Loman NJ.
PMID: 24812216
Genome Announc. 2014 May 08;2(3). doi: 10.1128/genomeA.00355-14.

We report the draft genome assembly of Elizabethkingia meningoseptica strain 502. The sample was isolated from the wound of a repatriated military serviceperson who suffered major trauma from an improvised explosive device (IED), resulting in wounds with extensive environmental...

Cite
Quick J, Constantinidou C, Pallen MJ, et al. Draft Genome Sequence of Elizabethkingia meningoseptica Isolated from a Traumatic Wound. Genome Announc. 2014;2(3)doi: 10.1128/genomeA.00355-14.
Quick, J., Constantinidou, C., Pallen, M. J., Oppenheim, B., & Loman, N. J. (2014). Draft Genome Sequence of Elizabethkingia meningoseptica Isolated from a Traumatic Wound. Genome announcements, 2(3), . https://doi.org/10.1128/genomeA.00355-14
Quick, Joshua, et al. "Draft Genome Sequence of Elizabethkingia meningoseptica Isolated from a Traumatic Wound." Genome announcements vol. 2,3 (2014). doi: https://doi.org/10.1128/genomeA.00355-14
Quick J, Constantinidou C, Pallen MJ, Oppenheim B, Loman NJ. Draft Genome Sequence of Elizabethkingia meningoseptica Isolated from a Traumatic Wound. Genome Announc. 2014 May 08;2(3). doi: 10.1128/genomeA.00355-14. PMID: 24812216; PMCID: PMC4014684.
Copy Download .nbib Format: NLM
Complete Genome Sequence of Uropathogenic Escherichia coli Strain CI5.

Genome announcements

Mehershahi KS, Abraham SN, Chen SL.
PMID: 26021932
Genome Announc. 2015 May 28;3(3). doi: 10.1128/genomeA.00558-15.

Escherichia coli represents the primary etiological agent responsible for urinary tract infections, one of the most common infections in humans. We report here the complete genome sequence of uropathogenic Escherichia coli strain CI5, a clinical pyelonephritis isolate used for...

Cite
Mehershahi KS, Abraham SN, Chen SL. Complete Genome Sequence of Uropathogenic Escherichia coli Strain CI5. Genome Announc. 2015;3(3)doi: 10.1128/genomeA.00558-15.
Mehershahi, K. S., Abraham, S. N., & Chen, S. L. (2015). Complete Genome Sequence of Uropathogenic Escherichia coli Strain CI5. Genome announcements, 3(3), . https://doi.org/10.1128/genomeA.00558-15
Mehershahi, Kurosh S, et al. "Complete Genome Sequence of Uropathogenic Escherichia coli Strain CI5." Genome announcements vol. 3,3 (2015). doi: https://doi.org/10.1128/genomeA.00558-15
Mehershahi KS, Abraham SN, Chen SL. Complete Genome Sequence of Uropathogenic Escherichia coli Strain CI5. Genome Announc. 2015 May 28;3(3). doi: 10.1128/genomeA.00558-15. PMID: 26021932; PMCID: PMC4447917.
Copy Download .nbib Format: NLM
MO-F-BRA-02: Evaluation of 4D CT to 4D Cone-Beam CT Deformable Image Registration for Lung Cancer Adaptive Radiation Therapy.

Medical physics

Balik S, Hugo G, Weiss E, Jan N, Roman N, Sleeman W, Fatyga M, Christensen G, Murphy M, Lu J, Keall P, Williamson J.
PMID: 28518270
Med Phys. 2012 Jun;39(6):3875. doi: 10.1118/1.4735821.

PURPOSE: To evaluate two deformable image registration (DIR) algorithms for the purpose of contour mapping to support image guided adaptive radiotherapy (IGART) with 4D cone beam CT (4DCBCT).METHODS: Eleven locally advanced non-small cell lung cancer (NSCLC) patients underwent one...

Cite
Balik S, Hugo G, Weiss E, et al. MO-F-BRA-02: Evaluation of 4D CT to 4D Cone-Beam CT Deformable Image Registration for Lung Cancer Adaptive Radiation Therapy. Med Phys. 2012;39(6):3875doi: 10.1118/1.4735821.
Balik, S., Hugo, G., Weiss, E., Jan, N., Roman, N., Sleeman, W., Fatyga, M., Christensen, G., Murphy, M., Lu, J., Keall, P., & Williamson, J. (2012). MO-F-BRA-02: Evaluation of 4D CT to 4D Cone-Beam CT Deformable Image Registration for Lung Cancer Adaptive Radiation Therapy. Medical physics, 39(6), 3875. https://doi.org/10.1118/1.4735821
Balik, S, et al. "MO-F-BRA-02: Evaluation of 4D CT to 4D Cone-Beam CT Deformable Image Registration for Lung Cancer Adaptive Radiation Therapy." Medical physics vol. 39,6 (2012): 3875. doi: https://doi.org/10.1118/1.4735821
Balik S, Hugo G, Weiss E, Jan N, Roman N, Sleeman W, Fatyga M, Christensen G, Murphy M, Lu J, Keall P, Williamson J. MO-F-BRA-02: Evaluation of 4D CT to 4D Cone-Beam CT Deformable Image Registration for Lung Cancer Adaptive Radiation Therapy. Med Phys. 2012 Jun;39(6):3875. doi: 10.1118/1.4735821. PMID: 28518270.
Copy Download .nbib Format: NLM
Cross-reactive antibodies enhance live attenuated virus infection for increased immunogenicity.

Nature microbiology

Chan KR, Wang X, Saron WAA, Gan ES, Tan HC, Mok DZL, Zhang SL, Lee YH, Liang C, Wijaya L, Ghosh S, Cheung YB, Tannenbaum SR, Abraham SN, St John AL, Low JGH, Ooi EE.
PMID: 27642668
Nat Microbiol. 2016 Sep 19;1:16164. doi: 10.1038/nmicrobiol.2016.164.

Vaccination has achieved remarkable successes in the control of childhood viral diseases. To control emerging infections, however, vaccines will need to be delivered to older individuals who, unlike infants, probably have had prior infection or vaccination with related viruses...

Cite
Chan KR, Wang X, Saron WAA, et al. Cross-reactive antibodies enhance live attenuated virus infection for increased immunogenicity. Nat Microbiol. 2016;1:16164doi: 10.1038/nmicrobiol.2016.164.
Chan, K. R., Wang, X., Saron, W. A. A., Gan, E. S., Tan, H. C., Mok, D. Z. L., Zhang, S. L., Lee, Y. H., Liang, C., Wijaya, L., Ghosh, S., Cheung, Y. B., Tannenbaum, S. R., Abraham, S. N., St John, A. L., Low, J. G. H., & Ooi, E. E. (2016). Cross-reactive antibodies enhance live attenuated virus infection for increased immunogenicity. Nature microbiology, 116164. https://doi.org/10.1038/nmicrobiol.2016.164
Chan, Kuan Rong, et al. "Cross-reactive antibodies enhance live attenuated virus infection for increased immunogenicity." Nature microbiology vol. 1 (2016): 16164. doi: https://doi.org/10.1038/nmicrobiol.2016.164
Chan KR, Wang X, Saron WAA, Gan ES, Tan HC, Mok DZL, Zhang SL, Lee YH, Liang C, Wijaya L, Ghosh S, Cheung YB, Tannenbaum SR, Abraham SN, St John AL, Low JGH, Ooi EE. Cross-reactive antibodies enhance live attenuated virus infection for increased immunogenicity. Nat Microbiol. 2016 Sep 19;1:16164. doi: 10.1038/nmicrobiol.2016.164. PMID: 27642668; PMCID: PMC7097525.
Copy Download .nbib Format: NLM
Mobile real-time surveillance of Zika virus in Brazil.

Genome medicine

Faria NR, Sabino EC, Nunes MR, Alcantara LC, Loman NJ, Pybus OG.
PMID: 27683027
Genome Med. 2016 Sep 29;8(1):97. doi: 10.1186/s13073-016-0356-2.

The World Health Organization has declared Zika virus an international public health emergency. Knowledge of Zika virus genomic epidemiology is currently limited due to challenges in obtaining and processing samples for sequencing. The ZiBRA project is a United Kingdom-Brazil...

Cite
Faria NR, Sabino EC, Nunes MR, et al. Mobile real-time surveillance of Zika virus in Brazil. Genome Med. 2016;8(1):97doi: 10.1186/s13073-016-0356-2.
Faria, N. R., Sabino, E. C., Nunes, M. R., Alcantara, L. C., Loman, N. J., & Pybus, O. G. (2016). Mobile real-time surveillance of Zika virus in Brazil. Genome medicine, 8(1), 97. https://doi.org/10.1186/s13073-016-0356-2
Faria, Nuno Rodrigues, et al. "Mobile real-time surveillance of Zika virus in Brazil." Genome medicine vol. 8,1 (2016): 97. doi: https://doi.org/10.1186/s13073-016-0356-2
Faria NR, Sabino EC, Nunes MR, Alcantara LC, Loman NJ, Pybus OG. Mobile real-time surveillance of Zika virus in Brazil. Genome Med. 2016 Sep 29;8(1):97. doi: 10.1186/s13073-016-0356-2. PMID: 27683027; PMCID: PMC5041528.
Copy Download .nbib Format: NLM
A Mast Cell Degranulation Screening Assay for the Identification of Novel Mast Cell Activating Agents.

MedChemComm

Staats HF, Kirwan SM, Choi HW, Shelburne CP, Abraham SN, Leung GY, Chen DY.
PMID: 23667736
Medchemcomm. 2013 Jan 01;4(1). doi: 10.1039/C2MD20073B.

The development and use of vaccines and their ability to prevent infection/disease is a shining example of the benefit of biomedical research. Modern vaccines often utilize subunit immunogens that exhibit minimal immunogenicity and require the use of adjuvants to...

Cite
Staats HF, Kirwan SM, Choi HW, et al. A Mast Cell Degranulation Screening Assay for the Identification of Novel Mast Cell Activating Agents. Medchemcomm. 2013;4(1)doi: 10.1039/C2MD20073B.
Staats, H. F., Kirwan, S. M., Choi, H. W., Shelburne, C. P., Abraham, S. N., Leung, G. Y., & Chen, D. Y. (2013). A Mast Cell Degranulation Screening Assay for the Identification of Novel Mast Cell Activating Agents. MedChemComm, 4(1), . https://doi.org/10.1039/C2MD20073B
Staats, Herman F, et al. "A Mast Cell Degranulation Screening Assay for the Identification of Novel Mast Cell Activating Agents." MedChemComm vol. 4,1 (2013). doi: https://doi.org/10.1039/C2MD20073B
Staats HF, Kirwan SM, Choi HW, Shelburne CP, Abraham SN, Leung GY, Chen DY. A Mast Cell Degranulation Screening Assay for the Identification of Novel Mast Cell Activating Agents. Medchemcomm. 2013 Jan 01;4(1). doi: 10.1039/C2MD20073B. PMID: 23667736; PMCID: PMC3646400.
Copy Download .nbib Format: NLM
BRCA1 and BRCA2 mutations in ovarian cancer: Covariation with specific cytogenetic features.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Koul A, Malander S, Loman N, Pejovic T, Heim S, Willen R, Johannsson O, Olsson H, Ridderheim M, Borg Å.
PMID: 11240689
Int J Gynecol Cancer. 2000 Jul;10(4):289-295. doi: 10.1046/j.1525-1438.2000.010004289.x.

We analyzed 37 primary invasive carcinomas for BRCA1 and BRCA2 mutations by screening the entire coding regions of both genes. Seven predicted truncating mutations (four in BRCA1 and three in BRCA2) and one novel BRCA1 missense variant (S1542C) were...

Cite
Koul A, Malander S, Loman N, et al. BRCA1 and BRCA2 mutations in ovarian cancer: Covariation with specific cytogenetic features. Int J Gynecol Cancer. 2000;10(4):289-295doi: 10.1046/j.1525-1438.2000.010004289.x.
Koul, A., Malander, S., Loman, N., Pejovic, T., Heim, S., Willen, R., Johannsson, O., Olsson, H., Ridderheim, M., & Borg Å. (2000). BRCA1 and BRCA2 mutations in ovarian cancer: Covariation with specific cytogenetic features. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 10(4), 289-295. https://doi.org/10.1046/j.1525-1438.2000.010004289.x
Koul, A., et al. "BRCA1 and BRCA2 mutations in ovarian cancer: Covariation with specific cytogenetic features." International journal of gynecological cancer : official journal of the International Gynecological Cancer Society vol. 10,4 (2000): 289-295. doi: https://doi.org/10.1046/j.1525-1438.2000.010004289.x
Koul A, Malander S, Loman N, Pejovic T, Heim S, Willen R, Johannsson O, Olsson H, Ridderheim M, Borg Å. BRCA1 and BRCA2 mutations in ovarian cancer: Covariation with specific cytogenetic features. Int J Gynecol Cancer. 2000 Jul;10(4):289-295. doi: 10.1046/j.1525-1438.2000.010004289.x. PMID: 11240689.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 270 entries